SCHEMBL6874432

SCHEMBL6874432

CC1(C(N)=O)CCCCCC1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
FFAR3 O14843 1/20 0.39
PKM P14618 1/20 0.39
CETP P11597 2/20 0.35
LMNA P02545 2/20 0.35
TDP1 Q9NUW8 1/20 0.34
P2RX7 Q99572 1/20 0.34
TSHR P16473 2/20 0.33
CYP2C19 P33261 2/20 0.33
USP2 O75604 1/20 0.33
CYP1A2 P05177 1/20 0.33
BLM P54132 1/20 0.33
CACNA2D1 P54289 1/20 0.33
CCR2 P41597 1/20 0.33
KDM4E B2RXH2 1/20 0.32
KMT2A Q03164 1/20 0.32
HSD11B1 P28845 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL516698 1.00 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2FFAR3PKMCETP
SCHEMBL7632840 1.00 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2FFAR3PKMCETP
Hydrochloric Acid SCHEMBL7274491 0.97 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2FFAR3PKMCETP
SCHEMBL1536078 0.97
SCHEMBL15340982 0.92 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2FFAR3PKMLMNA
SCHEMBL540102 0.92
SCHEMBL25489834 0.91 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2FFAR3PKMCETP
Hydrochloric Acid SCHEMBL4622019 0.89
Formic Acid SCHEMBL31251469 0.87 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2FFAR3PKMTDP1
SCHEMBL457922 0.85

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9556187-B2 Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2017-01-31 US disclosed
US-20160102102-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-04-14 US disclosed
EP-1438309-A1 QUINUCLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS M2 AND/OR M3 MUSCARINIC RECEPTOR INHIBITORS UCB, S.A. (BE) 2004-07-21 EP disclosed
WO-2003033495-A1 QUINUCLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS M2 AND/OR M3 MUSCARINIC RECEPTOR INHIBITORS UCB, S.A. (BE) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160102102-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS JAK2, JAK1, JAK3 ALDH1A1 3086/4885SMN1; SMN2 4522/4885FFAR3 4301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.